HLB Co., Ltd. HLB Co., Ltd.

HLB Co., Ltd.

028300

株式のランク #4130
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
株価
$31.27
時価総額
$4.16B
変化(1日)
6.78%
変化(1年)
1.26%
国
KR
取引 HLB Co., Ltd. (028300)

カテゴリー

Healthcare
HLB Co., Ltd.(028300)の収益
Jun 2026 時点の収益 TTM: $67.40M
HLB Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $67.40M です。2023 年には $33.14M の収益があり、これは 2022 年の $142.41M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
HLB Co., Ltd. の収益履歴(2012 ~ 2026)
各年末の収益
年 収益 変化
2026 (TTM) $67.40M 45.45%
2024 $46.34M 39.83%
2023 $33.14M -76.73%
2022 $142.41M 142.47%
2021 $58.73M 13.50%
2020 $51.75M 55.52%
2019 $33.27M 2.38%
2018 $32.50M 50.54%
2017 $21.59M -13.64%
2016 $25.00M -23.62%
2015 $32.73M -3.69%
2014 $33.98M 71.94%
2013 $19.76M -59.26%
2012 $48.51M 0.00%
同業他社の収益
企業 収益 収益の差 国
$12.62B 18,631.01%
US
$2.23B 3,205.74%
US
$15.74B 23,260.28%
AU
$6.02B 8,833.94%
NL
- -
CH